| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/14/2004 | EP1379280A2 Immunogenic complex |
| 01/14/2004 | EP1379277A2 Polyclonal populations of bispecific molecules and methods of production and uses thereof |
| 01/14/2004 | EP1379276A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/14/2004 | EP1379273A2 Nucleic acid adjuvants |
| 01/14/2004 | EP1379272A2 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies |
| 01/14/2004 | EP1379270A1 Method of inducing immune tolerance |
| 01/14/2004 | EP1379263A2 Mutated mhc molecules for use in immune suppression |
| 01/14/2004 | EP1379125A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 01/14/2004 | EP0690991B2 Novel anticoagulant cofactor activity |
| 01/14/2004 | CN1468309A Anti-il-12 antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468308A Anti-tnf antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468307A Anti-dual integrin antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468301A Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes |
| 01/14/2004 | CN1468259A Immunotherapy for chronic myelocytic leukemia |
| 01/14/2004 | CN1468256A Purification of hbv antigens for use in vaccines |
| 01/14/2004 | CN1468124A Method and composition for altering a t cell mediated pathology |
| 01/14/2004 | CN1468123A Method and composition for altering a b cell mediated pathology |
| 01/14/2004 | CN1468109A 疫苗组合物 Vaccine composition |
| 01/14/2004 | CN1468093A Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 01/14/2004 | CN1468091A Vaccine composition and stabilisation method |
| 01/14/2004 | CN1468089A Microparticles for delivery of the heterologous nucleic acids |
| 01/14/2004 | CN1467293A Infectious bursal disease virus (IBDV) polyprotein gene (VP2/VP4/VP3), eukaryon expressing plasmid, DNA vaccine |
| 01/14/2004 | CN1467223A Recombinated anti-CD25 monoclonal antibody, coding sequence and application |
| 01/14/2004 | CN1467221A Preparation and application of tubercle bacillus CFP-10, ESAT-6 and CD40L fusion bacterin |
| 01/14/2004 | CN1466996A Human SARS coronary virus receptor inhibitor |
| 01/14/2004 | CN1134452C Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/14/2004 | CN1134451C Inhibitor of collagen-stimulated platelet aggregation |
| 01/14/2004 | CN1134266C Methods for inducing T cell tolerance to tissue or organ graft |
| 01/14/2004 | CN1134265C Phosphazene polyelectrolytes as immunoadjuvants |
| 01/13/2004 | US6677444 Isolated dna encoding melanoma tumor-associated antigen |
| 01/13/2004 | US6677435 Includes an active therapeutic agent joined to a blocking moiety sensitive to the catalytic action of molecules having retro- aldol and retro-michael catalytic activity; antitumor; anticarcinogenic agents |
| 01/13/2004 | US6677433 Stabilization of hypoallergenic, hyperdigestible previously reduced proteins |
| 01/13/2004 | US6677127 Nucleic acid respiratory syncytial virus vaccines |
| 01/13/2004 | US6677126 Antibody for human translational regulator |
| 01/13/2004 | US6676985 Bovine lactation associated immunotropic protein (CD14), encoding gene and application in B cell activation |
| 01/13/2004 | US6676958 Adjuvant composition for mucosal and injection delivered vaccines |
| 01/13/2004 | US6676950 Administration of at least one antagonist specific for the neurokinin receptor family for inhibiting hiv infection in a patient |
| 01/13/2004 | US6676949 Two-step immunization procedure against Chlamydia infection |
| 01/13/2004 | US6676948 Haemophilus adherence and penetration proteins |
| 01/13/2004 | US6676946 Dendrimeric polylysine having bonded epitopes; cancer immuno-therapy |
| 01/13/2004 | US6676945 Induction immunology response |
| 01/13/2004 | US6676944 Vaccine containing a peroxiredoxin and/or a β-tubulin |
| 01/13/2004 | US6676943 Human complement C3-degrading protein from Streptococcus pneumoniae |
| 01/13/2004 | US6676942 Undergoes polymerase chain reaction with primers prospa1-a4 but not prospa1-a2 |
| 01/13/2004 | US6676941 For inhibiting angiogenesis and induce tumor regression; cancer therapy |
| 01/13/2004 | US6676939 Methods of modulating IL-174 response |
| 01/13/2004 | US6676938 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group B streptococcal carbohydrates |
| 01/13/2004 | US6676931 Buccal, polar and non-polar spray or capsule |
| 01/13/2004 | US6676924 CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| 01/13/2004 | CA2112811C Continuous cell line and vaccine against avian coccidia |
| 01/08/2004 | WO2004003544A1 Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders |
| 01/08/2004 | WO2004003511A2 Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance |
| 01/08/2004 | WO2004003215A1 Method of isolating biologically active fraction containing clinically acceptable native slipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides |
| 01/08/2004 | WO2004003183A1 Immunoliposome conjugated with anti-upa antibody |
| 01/08/2004 | WO2004003166A2 Antibodies and uses thereof |
| 01/08/2004 | WO2004003161A2 Immunogenic mycoplasma hyopneumoniae polypeptides |
| 01/08/2004 | WO2004003160A2 Use of adhesion molecules as bond stress-enhanced nanoscale binding switches |
| 01/08/2004 | WO2004003158A2 Methods and compositions for modulating and detecting wisp activity |
| 01/08/2004 | WO2004003157A2 Gene regulation in transgenic animals using a transposon-based vector |
| 01/08/2004 | WO2004003153A2 Live replicating spumavirus vector |
| 01/08/2004 | WO2004003145A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/08/2004 | WO2004003144A2 Antibodies that specifically bind to reg iv |
| 01/08/2004 | WO2004003143A2 Viruses and virus-like particles for multiple antigen and target display |
| 01/08/2004 | WO2004003017A1 Avian cytokines, such il-12, comprising a p40 and/or p35 subunit(s) |
| 01/08/2004 | WO2004003011A2 Nuclear hormone receptor |
| 01/08/2004 | WO2004003009A2 Francisella tularensis immunogenic proteins and dna encoding these |
| 01/08/2004 | WO2004002535A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 01/08/2004 | WO2004002528A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | WO2004002527A1 Compositions against chicken coccidiosis |
| 01/08/2004 | WO2004002526A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 01/08/2004 | WO2004002525A1 Use of antibodies against flt-1 for the treatment of osteoporosis |
| 01/08/2004 | WO2004002524A1 Placental growth factor as a target for the treatment of osteoporosis |
| 01/08/2004 | WO2004002523A1 Medicament for the treatment of diseases due to infection by neisseria meningitidis |
| 01/08/2004 | WO2004002522A1 Method of transforming autoimmune-disease-causing hapten-antigens (hapigens) of an organism into complete antigens |
| 01/08/2004 | WO2004002521A1 Preparation of vaccines |
| 01/08/2004 | WO2004002517A1 Diagnostics/preventives/re medies for respiratory diseases |
| 01/08/2004 | WO2004002500A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | WO2004002431A2 Humanized anti-lymphotoyin beta receptor antibodies |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002421A2 Method for the treatment of multiple sclerosis |
| 01/08/2004 | WO2004002415A2 Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| 01/08/2004 | WO2004002412A2 A method and composition to elicit an effective autologous antitumoral immune response in a patient |
| 01/08/2004 | WO2004002408A2 Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase |
| 01/08/2004 | WO2003093455A3 Adenovirus vectors for immunotherapy |
| 01/08/2004 | WO2003093315A3 Specific antibody fragments for the human carcinoembryonic antigen (cea) |
| 01/08/2004 | WO2003091387A3 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 01/08/2004 | WO2003086315A3 Tyrosine kinase inhibitors |
| 01/08/2004 | WO2003085090A3 A human ribonucleotide reductase m2 subunit |
| 01/08/2004 | WO2003080839A3 Antigen fragments for the diagnosis of toxoplasma gondii |
| 01/08/2004 | WO2003080665A3 Antibody that binds to a dimer of a prion protein for the treatment of tse infection |
| 01/08/2004 | WO2003068812A3 Immune-modulating peptide made of s. aureus enterotoxin b |
| 01/08/2004 | WO2003063766A3 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 01/08/2004 | WO2003050135A3 Use a parapox b2l protein to modify immune responses to administered antigens |
| 01/08/2004 | WO2003047618A3 Immunotherapeutic methods and systems |
| 01/08/2004 | WO2003020876A3 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 01/08/2004 | WO2003008533A3 Method for virus propagation |
| 01/08/2004 | WO2002099036A3 Inhibition of neurodegeneration |
| 01/08/2004 | WO2002095067A3 INTERFERON α-14 POLYMORPHISM |
| 01/08/2004 | WO2002095048A3 Methods for genetic immunization |
| 01/08/2004 | WO2002091996A3 Methods for treating cancer |